038 Stock Chart & Stats
€10.43
-€0.38(-1.37%)
At close: 4:00 PM EST
€10.43
-€0.38(-1.37%)
Day’s Range― - ―
52-Week Range€8.12 - €16.55
Previous CloseN/A
Volume0.00
Average Volume (3M)3.00
Market Cap
€1.75B
Enterprise Value€2.21B
Total Cash (Recent Filing)€441.80M
Total Debt (Recent Filing)€234.94M
Price to Earnings (P/E)―
Beta0.78
Next Earnings
Jul 23, 2026EPS Estimate
-0.29Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.53
Shares Outstanding115,820,940
10 Day Avg. Volume1
30 Day Avg. Volume3
Financial Highlights & Ratios
PEG Ratio0.49
Price to Book (P/B)4.23
Price to Sales (P/S)2.20
P/FCF Ratio-19.05
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€22.40Price Target Upside114.79% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
EPS Forecast (FY)-1.4
Revenue Forecast (FY)€617.22M
Bulls Say, Bears Say
Bulls Say
Gross Margin StrengthSustained high gross margins (~75%–78%) reflect favorable consumable economics and supplier cost improvements. Durable margin leverage from recurring consumable sales supports long‑term profitability potential as active patient volumes scale, helping absorb fixed R&D and commercialization costs.
Recurring Patient Base GrowthActive patient growth underpins a recurring revenue model tied to ongoing device use and consumable replacement. A steadily expanding installed base increases revenue predictability, creates upsell and retention opportunities, and enhances operating leverage as unit economics improve with scale across markets.
Regulatory / Indication ExpansionCE Mark for pancreatic cancer materially expands addressable market into a high‑unmet oncology segment. Regulatory approval and imminent German rollout enable durable new revenue streams, stronger clinical credibility, and a foundation for multi‑market commercialization in a therapy area with limited alternatives.
Bears Say
Negative Cash GenerationTrailing‑twelve‑month negative operating and free cash flow indicate ongoing cash burn despite margin strength. Continued reliance on external financing or drawdown of liquidity risks capital constraints over time and can pressure strategic investments or force dilution if losses persist.
Clinical Trial Setback (TRIDENT)A Phase 3 miss for earlier TTFields initiation limits evidence for a broader label expansion in glioblastoma. That constrains long‑term adoption scenarios tied to earlier‑stage use, may slow anticipated incremental market opportunities, and forces reassessment of trial strategy and commercial expectations.
Reimbursement Timing UncertaintyProlonged payer decision timelines create a durable barrier to realizing revenue from newly approved indications. Even with regulatory clearance, multi‑year reimbursement delays can restrict patient access, depress near‑term uptake, and lengthen the payback period on launch investments.
NovoCure News
038 FAQ
What was NovoCure Ltd.’s price range in the past 12 months?
NovoCure Ltd. lowest stock price was €8.12 and its highest was €16.55 in the past 12 months.
What is NovoCure Ltd.’s market cap?
NovoCure Ltd.’s market cap is €1.75B.
When is NovoCure Ltd.’s upcoming earnings report date?
NovoCure Ltd.’s upcoming earnings report date is Jul 23, 2026 which is in 12 days.
How were NovoCure Ltd.’s earnings last quarter?
NovoCure Ltd. released its earnings results on Apr 30, 2026. The company reported -€0.543 earnings per share for the quarter, missing the consensus estimate of -€0.448 by -€0.095.
Is NovoCure Ltd. overvalued?
According to Wall Street analysts NovoCure Ltd.’s price is currently Undervalued.
Does NovoCure Ltd. pay dividends?
NovoCure Ltd. does not currently pay dividends.
What is NovoCure Ltd.’s EPS estimate?
NovoCure Ltd.’s EPS estimate is -0.29.
How many shares outstanding does NovoCure Ltd. have?
NovoCure Ltd. has 115,820,940 shares outstanding.
What happened to NovoCure Ltd.’s price movement after its last earnings report?
NovoCure Ltd. reported an EPS of -€0.543 in its last earnings report, missing expectations of -€0.448. Following the earnings report the stock price went up 20.288%.
Which hedge fund is a major shareholder of NovoCure Ltd.?
Currently, no hedge funds are holding shares in DE:038
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
NovoCure Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€22.40 (114.79% Upside)
€22.40 (114.79% Upside)
Blogger Sentiment
Bullish
DE:038 Sentiment 70%
Sector Average 69%
Sector Average 69%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-4.94%
12-Months-Change
Fundamentals
Return on Equity
-50.82%
Trailing 12-Months
Asset Growth
-36.91%
Trailing 12-Months
Company Description
NovoCure Ltd.
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.
038 Company Deck
038 Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a broadly positive commercial and clinical outlook anchored by a strong start to 2026: double-digit revenue growth (12% YoY), rapid Optune Pax FDA approval and early U.S. launch traction, encouraging PANOVA-4 data, gross margin improvement, and tightened adjusted EBITDA versus prior year. These positives are tempered by a sizable one-time GAAP share‑based compensation charge that materially widened GAAP net loss and drove a large G&A increase, modest near-term revenue contribution from new indications, remaining reimbursement timing uncertainty, and ongoing trial strategy work for LUNAR-2. On balance, the company demonstrated substantive commercial momentum and multiple upcoming catalysts that outweigh the near-term accounting-driven losses and operational uncertainties.View all DE:038 earnings summaries038 Net revenue Breakdown
68.67% U.S.
11.82% Germany
8.74% Japan
6.22% Other EMEA
4.56% Greater China
038 Stock 12 Month Forecast
Average Price Target
€22.40
▲(114.79% Upside)
Technical Analysis
Options Prices
Currently, No data available
---